ArborGen FY25 results in line, navigating challenging market

ArborGen Holdings Limited (NZX: ARB) today announced its audited results for the year ended March 31, 2025, reporting revenue of USD 63.2m, down 7% year-on-year but 13% above FY23. Continued growth in Brazil saw sales up 11% in local currency, contributing 41% of total revenue. Seedling unit sales reached 328 million, with advanced genetics comprising 45% of the total. The results include a non-cash USD 21.8m impairment of intangible assets. Adjusted US GAAP EBITDA reached USD 8.8m, in line with guidance. US revenue decreased 9% year-on-year to USD 37.5m. The company is targeting a return to record earnings in FY26.